

# Anita Deswal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5338012/anita-deswal-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

9,546  
citations

48  
h-index

96  
g-index

183  
ext. papers

11,685  
ext. citations

6.2  
avg, IF

5.81  
L-index

#	Paper	IF	Citations
150	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment.. <i>Current Oncology Reports</i> , <b>2022</b> , 24, 543	6.3	1
149	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 734820	5.4	0
148	Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 763930	5.4	2
147	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , <b>2021</b> , 144, 1521-1523	16.7	8
146	COVID-19 myocarditis and long-term heart failure sequelae. <i>Current Opinion in Cardiology</i> , <b>2021</b> , 36, 234-240	11	
145	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018696	6	2
144	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 644264	5.4	0
143	Cardiovascular Toxicities of Androgen Deprivation Therapy. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 47	5.4	6
142	Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA. <i>Cardiology</i> , <b>2021</b> , 146, 481-488	1.6	
141	In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, JC69	8	
140	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1725-1735	12.3	9
139	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 162, e23-e106	1.5	9
138	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1329-1337	16.2	12
137	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 866-874	9.5	19
136	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 513-522	9.7	6
135	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 559-571	15.1	5
134	Obesity and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , <b>2021</b> , 17, 345-356	3.3	1

133	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. <i>Current Atherosclerosis Reports</i> , <b>2021</b> , 23, 61	6	0
132	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , <b>2021</b> , 47, 102132	11.3	3
131	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience.. <i>Open Heart</i> , <b>2021</b> , 8,	3	2
130	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 2095-2100	1.2	1
129	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. <i>International Journal of Obesity</i> , <b>2020</b> , 44, 1561-1567	5.5	8
128	Spironolactone in pulmonary arterial hypertension: results of a cross-over study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894019898030	2.7	14
127	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1682-1690	8.9	17
126	Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006513	7.6	56
125	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013757	6	102
124	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. <i>International Journal of Cardiology</i> , <b>2020</b> , 313, 1-8	3.2	7
123	Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 172-181	4.6	2
122	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , <b>2020</b> , 3, 113-120	9.6	4
121	Modern Radiotherapy and Risk of Cardiotoxicity. <i>Chemotherapy</i> , <b>2020</b> , 65, 65-76	3.2	5
120	An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. <i>Cardio-Oncology</i> , <b>2020</b> , 6, 20	2.8	1
119	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, e159-e240	15.1	82
118	In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, JC51	8	
117	Cardio-Oncology: Learning From the Old, Applying to the New. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 601893	5.4	1
116	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , <b>2020</b> , 22, 171	4.2	5

115	Iron deficiency and iron therapy in heart failure and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2020</b> , 29, 508-514	3.5	1
114	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014669	6	4
113	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , <b>2019</b> , 140, e294-e324	16.7	168
112	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 296-302	3	0
111	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2019</b> , 95, 1304-1317	9.9	96
110	Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , <b>2019</b> , 139, e879-e886	16.7	26
109	Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 380-400	3.3	58
108	Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 650-658	7.4	6
107	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e004817	5.8	1
106	Ularitide in Acute Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2018</b> , 6, 17-23	0.9	1
105	Prevention of "Failure": Is It a Failure of Prevention?. <i>Circulation</i> , <b>2018</b> , 137, 106-108	16.7	7
104	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2527-2536	15.1	29
103	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 223-233	7.4	3
102	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , <b>2018</b> , 21, 209-216	1.8	23
101	Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 620-622	7.4	3
100	In AF and HF, catheter ablation vs medical therapy reduced mortality and hospitalization for worsening HF. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, JC55	8	
99	NT-proBNP-guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, JC21	8	
98	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , <b>2018</b> , 14, 525-535	3.3	6

97	Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 56-63	7.9	18
96	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 233, 61-66	3.2	24
95	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 2030-2034	3	13
94	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e535-e578	16.7	164
93	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e579-e646	16.7	314
92	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , <b>2016</b> , 133, 631-8	16.7	69
91	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1144-1149	3	33
90	Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 145-9	3.3	18
89	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , <b>2015</b> , 36, 939-45	9.5	62
88	Transitions of care in heart failure: a scientific statement from the American Heart Association. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 384-409	7.6	143
87	Response to Letter Regarding Article, Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 840	7.6	2
86	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation</i> , <b>2015</b> , 131, 1763-71	16.7	173
85	Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 533-41	7.6	49
84	Coronary artery disease performance measures and statin use in patients with recent percutaneous coronary intervention or recent coronary artery bypass grafting (from the NCDR PINNACLE registry). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1013-8	3	3
83	Case report: isolated cardiac amyloidosis: an enigma unravelled. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2015</b> , 11, 53-8	2.1	3
82	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 1052-8	7.6	54
81	Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1803-1812	15.1	40
80	Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 21-6	3	96

79	Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. <i>Patient Preference and Adherence</i> , <b>2015</b> , 9, 1657-68	2.4	9
78	Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 111-21	15.1	50
77	Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 412-21	7.9	48
76	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 239-41	3.2	15
75	Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 560-8	3.3	33
74	Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 123-30	7.6	97
73	Relation between playing position and coronary artery calcium scores in retired National Football League players. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1836-40	3	10
72	Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2743-9	15.1	65
71	Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1834-8	3	46
70	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3741-6	3.2	35
69	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 1802-10	5.5	69
68	Worsening renal function is not associated with response to treatment in acute heart failure. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 1912-7	3.2	19
67	Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. <i>International Journal of Cardiology</i> , <b>2013</b> , 166, 394-8	3.2	17
66	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1268-77	27.4	762
65	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2533-43	27.4	322
64	Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 291-7	3.3	6
63	Ultrafiltration in decompensated heart failure with cardiorenal syndrome. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2296-304	59.2	577
62	New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 183-93	3.3	19

61	Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 176-82 <sup>3,3</sup>	72
60	Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 998-1005	15.1 455
59	Echocardiographic changes during treatment of acute decompensated heart failure: insights from the ESCAPE trial. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 792-8	3.3 28
58	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study. <i>Journal of Obesity &amp; Weight Loss Therapy</i> , <b>2012</b> , 2, 1-8	0 17
57	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 233-40	2.6 13
56	Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 152-9	7.6 210
55	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 653-9	7.6 98
54	Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. <i>American Heart Journal</i> , <b>2011</b> , 161, 567-73	4.9 43
53	Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, 634-42	3.3 138
52	Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. <i>International Journal of Cardiology</i> , <b>2011</b> , 150, 264-9	3.2 15
51	Diuretic strategies in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 797-805	59.2 1012
50	New predictive models of heart failure mortality using time-series measurements and ensemble models. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 456-62	7.6 26
49	Metformin use and mortality in ambulatory patients with diabetes and heart failure. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 53-8	7.6 137
48	A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. <i>International Journal of General Medicine</i> , <b>2010</b> , 3, 279-86	2.3 62
47	The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. <i>American Journal of Epidemiology</i> , <b>2010</b> , 172, 781-9	3.8 26
46	Predicting quality of life in veterans with heart failure: the role of disease severity, depression, and comorbid anxiety. <i>Behavioral Medicine</i> , <b>2010</b> , 36, 70-6	4.4 22
45	Biomarkers of inflammation in heart failure. <i>Heart Failure Reviews</i> , <b>2010</b> , 15, 331-41	5 153
44	Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 373-7	3 58

43	Mortality after hospitalization for heart failure in blacks compared to whites. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 694-700	3	15
42	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 449-55	4.4	6
41	Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 270-5	3	13
40	Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, 293-9	3.3	44
39	Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 422-8	15.1	144
38	Depression and anxiety in ambulatory patients with heart failure. <i>Psychosomatics</i> , <b>2009</b> , 50, 592-8	2.6	13
37	Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 415-26	15.1	125
36	Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 1-14, v	2.5	19
35	The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. <i>American Journal of Surgery</i> , <b>2008</b> , 196, 720-5	2.7	40
34	Decreasing body temperature predicts early rehospitalization in congestive heart failure. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 489-96	3.3	16
33	The metabolic syndrome and mortality in an ethnically diverse heart failure population. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 590-5	3.3	12
32	Advances in the treatment of heart failure with a preserved ejection fraction. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 233-40	2.1	5
31	Treatment of patients with heart failure and preserved ejection fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2008</b> , 10, 516-28	2.1	4
30	Anti-angiotensin therapy: new perspectives. <i>Cardiology Clinics</i> , <b>2007</b> , 25, 573-80; vi-vii	2.5	8
29	The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 32-6	15.1	29
28	Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. <i>American Heart Journal</i> , <b>2007</b> , 153, 515-22	4.9	24
27	Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 1228-31	3	68
26	Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. <i>American Heart Journal</i> , <b>2006</b> , 152, 348-54	4.9	56



25	Obesity as a prognostic factor in chronic symptomatic heart failure. <i>American Heart Journal</i> , <b>2005</b> , 150, 1233-9	4.9	69
24	Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. <i>Heart Failure Clinics</i> , <b>2005</b> , 1, 25-37	3.3	
23	Variation by race in factors contributing to heart failure hospitalizations. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 23-9	3.3	16
22	Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 206-12 <sup>3.3</sup>		4
21	Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology. <i>Current Cardiology Reports</i> , <b>2005</b> , 7, 178-83	4.2	25
20	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2005</b> , 2, 502-3		
19	Review: B-type natriuretic peptide consistently predicts death and cardiovascular events in heart failure. <i>ACP Journal Club</i> , <b>2005</b> , 143, 53		
18	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 1003-7	3	31
17	Aldosterone Receptor Blockers in the Treatment of Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2004</b> , 6, 327-334	2.1	5
16	Impact of race on health care utilization and outcomes in veterans with congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 778-84	15.1	99
15	Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. <i>Chest</i> , <b>2003</b> , 123, 716-24	5.3	72
14	Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1963-5	59.2	38
13	Perils of the random experiment. <i>American Journal of Therapeutics</i> , <b>2003</b> , 10, 112-21	1	
12	New therapeutics for chronic heart failure. <i>Annual Review of Medicine</i> , <b>2002</b> , 53, 59-74	17.4	54
11	The fragility of cardiovascular clinical trial results. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 247-53	3.3	6
10	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 390-8	3.3	86
9	Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. <i>Heart Failure Monitor</i> , <b>2002</b> , 3, 42-8		
8	Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. <i>Chest</i> , <b>2001</b> , 120, 453-9	5.3	16

7	Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. <i>Contemporary Clinical Trials</i> , <b>2001</b> , 22, 605-19		26
6	Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). <i>Circulation</i> , <b>2001</b> , 103, 2055-9	16.7	781
5	Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. <i>Circulation</i> , <b>1999</b> , 99, 3224-6	16.7	317
4	An overview of tumor necrosis factor alpha and the failing human heart. <i>Current Opinion in Cardiology</i> , <b>1999</b> , 14, 206-10	2.1	68
3	Quantification of the myocardial response to low-dose dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 615-23	3	133
2	The role of cytokines in disease progression in heart failure. <i>Current Opinion in Cardiology</i> , <b>1997</b> , 12, 218-23		61
1	Cardiac involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , <b>1996</b> , 22, 841-60	2.4	76